. 2022 Nov 5;10(11):2826. doi: 10.3390/biomedicines10112826

Table 1.

TIM-3 expression on tumor-associated immune cells and study observations related to expression.

Reference	Lymphocyte Subset	Types of Cells	Expression of Other Molecules	Observations
[26]	TILs	CD8⁺ T cells	PD-1, LAG-3, CTLA-4, PD-L1	expression assessment, correlations between subsets, survival prediction
[21]	ND	ND	-	expression assessment, correlation of TIM-3 polymorphisms with susceptibility to EOC
[28]	MALs, TILs, PBLs	γδ T cells	TIGIT, PD-1, OX40,CD39, CD73	expression assessment, correlations between subsets
	MALs, TILs, PBLs	Vδ1 T cells	TIGIT, PD-1, OX40,CD39, CD73
	MALs, TILs, PBLs	Vδ2 T cells	TIGIT, PD-1, OX40,CD39, CD73
[11]	TALs	CD4⁺ T cells	PD-1,LAG-3, CTLA-4	expression assessment, correlations between subsets, determination of clinical relevance and risk factors
	TALs	CD8⁺ T cells	PD-1,LAG-3, CTLA-4
	TILs	CD4⁺ T cells	PD-1,LAG-3, CTLA-4
	TILs	CD8⁺ T cells	PD-1,LAG-3, CTLA-4
	PBLs	CD4⁺ T cells	PD-1,LAG-3, CTLA-4
	PBLs	CD8⁺ T cells	PD-1,LAG-3, CTLA-4
[12]	TILs	CD4⁺ T cells	OX40	expression assessment, survival prediction;
[12]	TILs	CD8⁺ T cells	OX40	expression assessment, survival prediction;
[33]	TI	Tfh cells	PD-1	expression assessment, correlations between subsets
[33]	PB	Tfh cells	PD-1	expression assessment, correlations between subsets
[34]	PBMC	Treg	CTLA-4	expression assessment, survival prediction;
[34]	PBMC	CD8⁺ T cells	PD-1,CTLA-4	expression assessment, survival prediction;
[20]	ND	ND	PD-1, CTLA-4, LAG-3	expression assessment, correlation with immune cells subsets, survival prediction;
[35]	PBMCs	CD8⁺ T cells	CTLA-4, TIGIT, PD-1, LAG-3	expression assessment, immune checkpoint upregulation via CCL23
[36]	TILs	CD8⁺ T cells	PD-1	expression assessment, survival prediction, assessment of risk of recurrence
[36]	PBMCs	CD8⁺ T cells	PD-1
[37]	immune cells (not specified)	ND	PD-L1, IDO, LAG-3	expression assessment, correlation with TILs, prognostic impact
[38]	TILs	Treg	Foxp3	expression assessment, correlation with tumor size
[38]	PBMCs	Treg	Foxp3	expression assessment, correlation with tumor size
[39]	PBMCs	CD4⁺ T cells	-	expression assessment
[39]	TILs	CD4⁺ T cells	Foxp3, CD25	expression assessment
[40]	MALs	CD8⁺ T cells	PD-1, LAG-3, BTLA	expression assessment
[40]	MALs	CD4⁺ T cells	PD-1, LAG-3, BTLA	expression assessment

TALs—tumor-associated lymphocytes, TILs/TI—tumor-infiltrating lymphocytes, PBLs/PB—peripheral blood lymphocytes, MALs—malignant ascites lymphocytes, PBMCs—peripheral blood mononuclear cells, ND—no data.